BioCentury
ARTICLE | Financial News

RiboQuark raises $7.4 million in A round

January 8, 2014 1:30 AM UTC

Kunshan RiboQuark Pharmaceutical Technology Co. Ltd. (Kunshan, China) raised almost RMB45 million ($7.4 million) in a series A round led by BVCF. SBI Incubation; Kunshan Industrial Technology Research Institute Investment; and Kunshan Hongtu Hi-tech Venture Capital Management also participated.

RiboQuark is a JV between RNAi companies Suzhou Ribo Life Sciences Co. Ltd. (Kunshan, China) and Quark Pharmaceuticals Inc. RiboQuark's QPI-1007 is slated to start Phase III testing for non-arteritic anterior ischemic optic neuropathy (NA-AION) and Phase II testing for acute angle closure glaucoma. The JV has rights to the short interfering RNA (siRNA) that inhibits expression of caspase 2 (CASP2) in China and other undisclosed countries from Quark. ...